Avalon GloboCare Corp. Amends 8-K Filing to Correct Share Issuance Details; Closes \$2.8 Million Private Placement

Key Highlights for Investors

• Correction of Previous Filing: Avalon GloboCare Corp. (NASDAQ: ALBT) has filed an amended Form 8-K/A (“Amendment No. 1”) to correct an inadvertent error in the number of shares reported as being issued under Item 3.02 of its original March 2, 2026, 8-K filing.
• Private Placement Completed: The company closed a Private Placement on February 27, 2026, raising approximately \$2.8 million in net proceeds.
• Issuance of Securities: The financing involved the sale and issuance of shares, pre-funded warrants, Series A-1 and A-2 warrants, and placement agent warrants to certain institutional investors in a transaction exempt from SEC registration.
• Warrant Exercises: Significant warrant exercises occurred in February 2026, leading to the issuance of over 1.2 million shares with no cash proceeds to the company.
• Potential Price Sensitivity: The correction in share count, the inflow of new capital, and the dilution from new shares and warrants are all material information that could affect ALBT’s share price.

Detailed Article

Avalon GloboCare Corp. (NASDAQ: ALBT), a healthcare company, has issued an important update for shareholders and the investing public. On February 24, 2026, the company filed an amended Form 8-K/A to correct an error in its previously filed Form 8-K dated March 2, 2026. The amendment specifically addresses an incorrect number of shares reported as being issued under Item 3.02 (Unregistered Sales of Equity Securities) in the original filing. No other changes were made to the original report.

Details of the Amended Filing

Avalon GloboCare’s amendment clarifies the actual number of shares issued. This correction is significant as it impacts the company’s share count, potential dilution, and could influence the perception of the company’s recent capital activities among investors.

Private Placement Raises \$2.8 Million

On February 26, 2026, Avalon GloboCare entered into securities purchase agreements with institutional investors for the sale of:

• Common shares
• Pre-Funded Warrants
• Series A-1 Warrants
• Series A-2 Warrants
• Placement Agent Warrants

The transaction closed on February 27, 2026. The company expects to receive net proceeds of approximately \$2.8 million after deducting placement agent fees and offering expenses. Roth Capital Partners served as the financial advisor and received a cash fee of \$75,000.

The company plans to use the proceeds for continuing operating expenses and working capital. A portion may also be used for the repayment of certain outstanding debt.

Material Unregistered Issuance of Securities

The securities issued in the Private Placement, including shares, warrants, and agent warrants, as well as shares issuable upon exercise of these instruments, were not registered under the Securities Act of 1933. The company relied on exemptions under Section 4(a)(2) and Regulation D, which restrict resale and may limit immediate liquidity of these securities.

In addition, during February 2026, the company issued a total of 1,268,666 shares (287,411 on February 19, 230,733 on February 24, and 750,522 on February 26) upon net exercise of existing warrants. Notably, no cash proceeds were received from these exercises, as they were done on a net-exercise basis. The February 24 issuance triggered the disclosure under Item 3.02.

Press Releases

Avalon GloboCare issued press releases on February 26 and February 27, 2026, to announce the pricing and closing of the Private Placement, respectively. These press releases are furnished as exhibits to the amended filing.

Potential Impact on Shareholders and Share Price

• Dilution: The issuance of new shares and warrants will dilute existing shareholders. The total number of new shares issued, plus the shares potentially issuable under the new warrants and agent warrants, could be significant relative to the current float.
• Capital Raise: The successful completion of a \$2.8 million private placement strengthens the company’s balance sheet and provides additional operating capital, which may be viewed positively by the market if used effectively.
• Unregistered Securities and Possible Overhang: The securities issued are unregistered and restricted, potentially creating an overhang if and when they become eligible for resale, which could exert downward pressure on the share price.
• Correction of Prior Disclosure: The restatement of the number of shares issued helps ensure transparency and compliance, but may raise questions about internal controls and reporting accuracy.

Important Exhibits

The following documents are attached as exhibits and may be of interest to investors seeking details:

• Form of Pre-Funded Warrant
• Form of Placement Agent Warrant
• Form of Securities Purchase Agreement
• Form of Registration Rights Agreement
• Press Releases on Pricing and Closing

Conclusion

The amended 8-K/A filing is material and price-sensitive, as it corrects previous disclosure, documents a substantial capital raise, and discloses significant new share issuances and potential dilution. Shareholders should review the details and exhibits carefully, as these developments could impact the value of their holdings in Avalon GloboCare Corp.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to perform their own due diligence and consult with their financial advisors before making investment decisions. The author does not hold a position in Avalon GloboCare Corp. at the time of writing.

View Avalon GloboCare Corp. Historical chart here